DEFA14A: Phathom Pharmaceuticals Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Proxy Statement
Phathom Pharmaceuticals has scheduled its annual stockholder meeting for June 3, 2025, and is seeking votes on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.
Summary
- Phathom Pharmaceuticals will hold its annual stockholder meeting on June 3, 2025.
- Stockholders are being asked to vote on several key proposals.
- These include the election of two Class III directors, ratification of Ernst & Young LLP as the company's independent auditor, approval of executive compensation, and the frequency of advisory votes on executive pay.
- The board recommends voting 'For' all listed proposals.
- Stockholders can access meeting materials and vote online at www.ProxyVote.com.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, indicating a neutral sentiment. It reflects routine corporate governance procedures.
Positives
- The company is providing stockholders with multiple avenues to access proxy materials and vote, including online, phone, and email.
- The board is making clear recommendations on how to vote on each proposal.
Future Outlook
The document outlines the proposals to be voted on at the 2025 annual meeting, indicating the company's focus on corporate governance and shareholder engagement.
Industry Context
This is a standard proxy statement related to an annual meeting, a routine part of corporate governance for publicly traded companies. It allows shareholders to exercise their rights and influence company decisions.
Stakeholder Impact
- Shareholders have the opportunity to influence the company's direction through their votes.
- The outcome of the votes will impact the composition of the board, the selection of the auditor, and executive compensation practices.
Next Steps
- Stockholders should review the proxy materials and vote on the proposals before the deadlines.
- The company will hold its annual meeting on June 3, 2025.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Start of the fiscal year for which Ernst & Young LLP is being considered as the independent registered public accounting firm. |
| December 31, 2024 | End of the fiscal year for which Ernst & Young LLP is being considered as the independent registered public accounting firm. |
| May 20, 2025 | Deadline to request a paper or email copy of the proxy materials. |
| June 2, 2025 | Voting deadline: 11:59 PM ET. |
| June 3, 2025 | Annual Meeting date: 11:30 AM EDT. |
| December 31, 2025 | End of the fiscal year for which Ernst & Young LLP is being ratified. |
| 2028 | Year the Class III directors' term expires if elected. |
Keywords
Annual Meeting, Proxy Vote, Stockholders, Phathom Pharmaceuticals, Directors, Executive Compensation, Auditor, Ernst & Young
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.